Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,889
archived clinical trials in
Blood Cancer

A Safety Study of SGN-CD19A for Leukemia and Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas
Status: Enrolling
Updated:  2/2/2017
City of Hope National Medical Center
mi
from
Duarte, CA
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas
Status: Enrolling
Updated: 2/2/2017
City of Hope National Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas
Status: Enrolling
Updated:  2/2/2017
Mayo Clinic Florida
mi
from
Jacksonville, FL
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas
Status: Enrolling
Updated: 2/2/2017
Mayo Clinic Florida
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas
Status: Enrolling
Updated:  2/2/2017
All Children's Hospital
mi
from
St. Petersburg, FL
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas
Status: Enrolling
Updated: 2/2/2017
All Children's Hospital
mi
from
St. Petersburg, FL
Click here to add this to my saved trials
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas
Status: Enrolling
Updated:  2/2/2017
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas
Status: Enrolling
Updated: 2/2/2017
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas
Status: Enrolling
Updated:  2/2/2017
Children's Healthcare of Atlanta / Emory University
mi
from
Altanta, GA
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas
Status: Enrolling
Updated: 2/2/2017
Children's Healthcare of Atlanta / Emory University
mi
from
Altanta, GA
Click here to add this to my saved trials
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas
Status: Enrolling
Updated:  2/2/2017
Massachusetts General Hospital
mi
from
Boston, MA
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas
Status: Enrolling
Updated: 2/2/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas
Status: Enrolling
Updated:  2/2/2017
Boston Children's Hospital
mi
from
Boston, MA
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas
Status: Enrolling
Updated: 2/2/2017
Boston Children's Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas
Status: Enrolling
Updated:  2/2/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas
Status: Enrolling
Updated: 2/2/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas
Status: Enrolling
Updated:  2/2/2017
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas
Status: Enrolling
Updated: 2/2/2017
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas
Status: Enrolling
Updated:  2/2/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas
Status: Enrolling
Updated: 2/2/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome
Probiotic Enteric Regimen For Easing Complications of Transplant : A Pilot Study (PERFECT Trial)
Status: Enrolling
Updated:  2/2/2017
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome
Probiotic Enteric Regimen For Easing Complications of Transplant : A Pilot Study (PERFECT Trial)
Status: Enrolling
Updated: 2/2/2017
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Prospective Pilot Study of Bone Marrow and Peripheral Blood Samples From AML Patients to Characterize the Biologic Heterogeneity of the Disease Using Single Cell Network Profiling (SCNP)
Prospective Pilot Study of Bone Marrow and Peripheral Blood Samples From Acute Myeloid Leukemia (AML) Patients to Characterize the Biologic Heterogeneity of the Disease Using Single Cell Network Profiling (SCNP)
Status: Enrolling
Updated:  2/6/2017
MBRCC, West Virginia University
mi
from
Morgantown, WV
Prospective Pilot Study of Bone Marrow and Peripheral Blood Samples From AML Patients to Characterize the Biologic Heterogeneity of the Disease Using Single Cell Network Profiling (SCNP)
Prospective Pilot Study of Bone Marrow and Peripheral Blood Samples From Acute Myeloid Leukemia (AML) Patients to Characterize the Biologic Heterogeneity of the Disease Using Single Cell Network Profiling (SCNP)
Status: Enrolling
Updated: 2/6/2017
MBRCC, West Virginia University
mi
from
Morgantown, WV
Click here to add this to my saved trials
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
Status: Enrolling
Updated:  2/7/2017
Rady Children's Hospital - San Diego
mi
from
San Diego, CA
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
Status: Enrolling
Updated: 2/7/2017
Rady Children's Hospital - San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
Status: Enrolling
Updated:  2/7/2017
Riley Hospital for Children at IU Health
mi
from
Indianapolis, IN
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
Status: Enrolling
Updated: 2/7/2017
Riley Hospital for Children at IU Health
mi
from
Indianapolis, IN
Click here to add this to my saved trials
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
Status: Enrolling
Updated:  2/7/2017
Children's Hospital at Montefiore
mi
from
Bronx, NY
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
Status: Enrolling
Updated: 2/7/2017
Children's Hospital at Montefiore
mi
from
Bronx, NY
Click here to add this to my saved trials
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
Status: Enrolling
Updated:  2/7/2017
Maimonides Medical Center
mi
from
Brooklyn, NY
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
Status: Enrolling
Updated: 2/7/2017
Maimonides Medical Center
mi
from
Brooklyn, NY
Click here to add this to my saved trials
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
Status: Enrolling
Updated:  2/7/2017
NYU Langone Medical Center
mi
from
New York, NY
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
Status: Enrolling
Updated: 2/7/2017
NYU Langone Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
Status: Enrolling
Updated:  2/7/2017
Mount Sinai Hospital
mi
from
New York, NY
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
Status: Enrolling
Updated: 2/7/2017
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias
A Pharmacokinetic Study of Oral and Intravenous Clofarabine in Patients With High Risk Myelodysplasia and Acute Leukemias - Determination of Oral Bioavailability and the Effect of Cimetidine on Clofarabine Clearance
Status: Enrolling
Updated:  2/7/2017
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias
A Pharmacokinetic Study of Oral and Intravenous Clofarabine in Patients With High Risk Myelodysplasia and Acute Leukemias - Determination of Oral Bioavailability and the Effect of Cimetidine on Clofarabine Clearance
Status: Enrolling
Updated: 2/7/2017
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
AMG 319 Lymphoid Malignancy FIH
A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 319 in Adult Subjects With Relapsed or Refractory Lymphoid Malignancies
Status: Enrolling
Updated:  2/8/2017
Clinical Research Facility
mi
from
Salt Lake City, UT
AMG 319 Lymphoid Malignancy FIH
A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 319 in Adult Subjects With Relapsed or Refractory Lymphoid Malignancies
Status: Enrolling
Updated: 2/8/2017
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
AMG 319 Lymphoid Malignancy FIH
A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 319 in Adult Subjects With Relapsed or Refractory Lymphoid Malignancies
Status: Enrolling
Updated:  2/8/2017
Clinical Research Facility
mi
from
Hackensack, NJ
AMG 319 Lymphoid Malignancy FIH
A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 319 in Adult Subjects With Relapsed or Refractory Lymphoid Malignancies
Status: Enrolling
Updated: 2/8/2017
Clinical Research Facility
mi
from
Hackensack, NJ
Click here to add this to my saved trials
AMG 319 Lymphoid Malignancy FIH
A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 319 in Adult Subjects With Relapsed or Refractory Lymphoid Malignancies
Status: Enrolling
Updated:  2/8/2017
Clinical Research Facility
mi
from
Durham, NC
AMG 319 Lymphoid Malignancy FIH
A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 319 in Adult Subjects With Relapsed or Refractory Lymphoid Malignancies
Status: Enrolling
Updated: 2/8/2017
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
A Phase I/II Trial of Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
Status: Enrolling
Updated:  2/8/2017
Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center
mi
from
Sleepy Hollow, NY
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
A Phase I/II Trial of Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
Status: Enrolling
Updated: 2/8/2017
Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center
mi
from
Sleepy Hollow, NY
Click here to add this to my saved trials
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
A Phase I/II Trial of Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
Status: Enrolling
Updated:  2/8/2017
Memoral Sloan Kettering Cancer Center
mi
from
Basking Ridge, NJ
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
A Phase I/II Trial of Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
Status: Enrolling
Updated: 2/8/2017
Memoral Sloan Kettering Cancer Center
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
A Phase I/II Trial of Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
Status: Enrolling
Updated:  2/8/2017
Memorial Sloan-Kettering Cancer Center @ Suffolk
mi
from
Commack, NY
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
A Phase I/II Trial of Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
Status: Enrolling
Updated: 2/8/2017
Memorial Sloan-Kettering Cancer Center @ Suffolk
mi
from
Commack, NY
Click here to add this to my saved trials
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
A Phase I/II Trial of Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
Status: Enrolling
Updated:  2/8/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
A Phase I/II Trial of Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
Status: Enrolling
Updated: 2/8/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
A Phase I/II Trial of Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
Status: Enrolling
Updated:  2/8/2017
Memorial Sloan Kettering Cancer Center at Mercy Medical Center
mi
from
Rockville Centre, NY
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
A Phase I/II Trial of Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
Status: Enrolling
Updated: 2/8/2017
Memorial Sloan Kettering Cancer Center at Mercy Medical Center
mi
from
Rockville Centre, NY
Click here to add this to my saved trials
Phase I Study of CS-7017 and Bexarotene
A Phase I Study of a Combination of the Proteosome Proliferator-Activated Receptor Gamma Agonist, CS-7017 and the Retinoid X Receptor Agonist, Bexarotene
Status: Enrolling
Updated:  2/13/2017
Georgetown Lombardi Comprehensive Cancer Center
mi
from
Washington,
Phase I Study of CS-7017 and Bexarotene
A Phase I Study of a Combination of the Proteosome Proliferator-Activated Receptor Gamma Agonist, CS-7017 and the Retinoid X Receptor Agonist, Bexarotene
Status: Enrolling
Updated: 2/13/2017
Georgetown Lombardi Comprehensive Cancer Center
mi
from
Washington,
Click here to add this to my saved trials
Pilot Study Exploring the Use of Hyperbaric Oxygen in Autologous Peripheral Blood Stem Cell Transplantation
Pilot Study Exploring the Use of Hyperbaric Oxygen in Autologous Peripheral Blood Stem Cell Transplant
Status: Enrolling
Updated:  2/13/2017
University of Kansas Medical Center
mi
from
Kansas City, KA
Pilot Study Exploring the Use of Hyperbaric Oxygen in Autologous Peripheral Blood Stem Cell Transplantation
Pilot Study Exploring the Use of Hyperbaric Oxygen in Autologous Peripheral Blood Stem Cell Transplant
Status: Enrolling
Updated: 2/13/2017
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant
A Phase I/II Study of Cellular Immunotherapy With Donor Central Memory-derived Virus-specific CD8+ T-cells Engineered to Target CD19 for CD19+ Malignancies After Allogeneic Hematopoietic Stem Cell Transplant
Status: Enrolling
Updated:  2/14/2017
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant
A Phase I/II Study of Cellular Immunotherapy With Donor Central Memory-derived Virus-specific CD8+ T-cells Engineered to Target CD19 for CD19+ Malignancies After Allogeneic Hematopoietic Stem Cell Transplant
Status: Enrolling
Updated: 2/14/2017
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia
A Phase lb Study of the Safety, Feasibility, and Pharmacokinetics of AMG 386 Alone and in Combination With Low Dose Cytarabine in Acute Myeloid Leukemia (AML) Patients
Status: Enrolling
Updated:  2/14/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia
A Phase lb Study of the Safety, Feasibility, and Pharmacokinetics of AMG 386 Alone and in Combination With Low Dose Cytarabine in Acute Myeloid Leukemia (AML) Patients
Status: Enrolling
Updated: 2/14/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia
A Phase lb Study of the Safety, Feasibility, and Pharmacokinetics of AMG 386 Alone and in Combination With Low Dose Cytarabine in Acute Myeloid Leukemia (AML) Patients
Status: Enrolling
Updated:  2/14/2017
University of Rochester
mi
from
Rochester, NY
Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia
A Phase lb Study of the Safety, Feasibility, and Pharmacokinetics of AMG 386 Alone and in Combination With Low Dose Cytarabine in Acute Myeloid Leukemia (AML) Patients
Status: Enrolling
Updated: 2/14/2017
University of Rochester
mi
from
Rochester, NY
Click here to add this to my saved trials
A Open-label Study of Ultra-High Dose Dexamethasone for Relapsed Multiple Myeloma
A Phase II, Open-label, Single Center Study of Ultra-High Dose Dexamethasone (UHDD) Administered Intravenously and Orally as Monotherapy for the Treatment of Relapsed Multiple Myeloma
Status: Enrolling
Updated:  2/14/2017
Boston Med Ctr
mi
from
Boston, MA
A Open-label Study of Ultra-High Dose Dexamethasone for Relapsed Multiple Myeloma
A Phase II, Open-label, Single Center Study of Ultra-High Dose Dexamethasone (UHDD) Administered Intravenously and Orally as Monotherapy for the Treatment of Relapsed Multiple Myeloma
Status: Enrolling
Updated: 2/14/2017
Boston Med Ctr
mi
from
Boston, MA
Click here to add this to my saved trials
A Quality Improvement Approach to the Management of Chronic Lymphocytic Leukemia
A Quality Improvement Approach to the Management of Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  2/14/2017
Duke Cancer Network
mi
from
Durham, NC
A Quality Improvement Approach to the Management of Chronic Lymphocytic Leukemia
A Quality Improvement Approach to the Management of Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 2/14/2017
Duke Cancer Network
mi
from
Durham, NC
Click here to add this to my saved trials
Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma
A Study of Low-dose Lenalidomide After Non-myeloablative Allogeneic Stem Cell Transplant With Bortezomib as GVHD Prophylaxis in High Risk Multiple Myeloma
Status: Enrolling
Updated:  2/16/2017
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma
A Study of Low-dose Lenalidomide After Non-myeloablative Allogeneic Stem Cell Transplant With Bortezomib as GVHD Prophylaxis in High Risk Multiple Myeloma
Status: Enrolling
Updated: 2/16/2017
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone
Status: Enrolling
Updated:  2/22/2017
Baylor University Medical Center
mi
from
Dallas, TX
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone
Status: Enrolling
Updated: 2/22/2017
Baylor University Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone
Status: Enrolling
Updated:  2/22/2017
Cancer Care Centers of South Texas
mi
from
San Antonio, TX
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone
Status: Enrolling
Updated: 2/22/2017
Cancer Care Centers of South Texas
mi
from
San Antonio, TX
Click here to add this to my saved trials
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone
Status: Enrolling
Updated:  2/22/2017
Cleveland Clinic
mi
from
Cleveland, OH
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone
Status: Enrolling
Updated: 2/22/2017
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone
Status: Enrolling
Updated:  2/22/2017
Colorado Blood Cancer Institute
mi
from
Denver, CO
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone
Status: Enrolling
Updated: 2/22/2017
Colorado Blood Cancer Institute
mi
from
Denver, CO
Click here to add this to my saved trials
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone
Status: Enrolling
Updated:  2/22/2017
Florida Cancer Specialist North
mi
from
St Petersburg, FL
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone
Status: Enrolling
Updated: 2/22/2017
Florida Cancer Specialist North
mi
from
St Petersburg, FL
Click here to add this to my saved trials
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone
Status: Enrolling
Updated:  2/22/2017
Florida Cancer Specialist South
mi
from
Fort Myers, FL
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone
Status: Enrolling
Updated: 2/22/2017
Florida Cancer Specialist South
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone
Status: Enrolling
Updated:  2/22/2017
John Theurer Cancer Center
mi
from
Hackensak, NJ
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone
Status: Enrolling
Updated: 2/22/2017
John Theurer Cancer Center
mi
from
Hackensak, NJ
Click here to add this to my saved trials
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone
Status: Enrolling
Updated:  2/22/2017
Oncology Hematology Care
mi
from
Cincinati, OH
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone
Status: Enrolling
Updated: 2/22/2017
Oncology Hematology Care
mi
from
Cincinati, OH
Click here to add this to my saved trials
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone
Status: Enrolling
Updated:  2/22/2017
Southern Cancer Center
mi
from
Mobile, AL
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone
Status: Enrolling
Updated: 2/22/2017
Southern Cancer Center
mi
from
Mobile, AL
Click here to add this to my saved trials
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone
Status: Enrolling
Updated:  2/22/2017
Sutter Medical Group
mi
from
Sacramento, CA
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone
Status: Enrolling
Updated: 2/22/2017
Sutter Medical Group
mi
from
Sacramento, CA
Click here to add this to my saved trials
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone
Status: Enrolling
Updated:  2/22/2017
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone
Status: Enrolling
Updated: 2/22/2017
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Click here to add this to my saved trials
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone
Status: Enrolling
Updated:  2/22/2017
Tennessee Oncology-Chattanooga
mi
from
Chattanooga, TN
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone
Status: Enrolling
Updated: 2/22/2017
Tennessee Oncology-Chattanooga
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone
Status: Enrolling
Updated:  2/22/2017
University of Kansas Cancer Center
mi
from
Westwood, KA
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone
Status: Enrolling
Updated: 2/22/2017
University of Kansas Cancer Center
mi
from
Westwood, KA
Click here to add this to my saved trials
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone
Status: Enrolling
Updated:  2/22/2017
University of Kentucky
mi
from
Lexington, KY
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone
Status: Enrolling
Updated: 2/22/2017
University of Kentucky
mi
from
Lexington, KY
Click here to add this to my saved trials
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone
Status: Enrolling
Updated:  2/22/2017
The University of Oklahoma Health Science Center
mi
from
Oklahoma City, OK
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone
Status: Enrolling
Updated: 2/22/2017
The University of Oklahoma Health Science Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials